Pune, India -- (SBWIRE) -- 02/09/2018 -- The Global Anal Fissure Treatment Market is expected to reach $ 2.6 billion by the end of 2023, this market is projected to growing at a CAGR of ~ 5.2 % during 2017-2023.

The anal fissure treatment market is chiefly driven by rise in constipation, diarrhoea, tuberculosis, carcinoma, acquired immunodeficiency syndrome (AIDS), and inflammatory bowel disease etc. Other drivers of anal fissures include anal sex, childbirth trauma in women, Crohn's disease, and ulcerative colitis etc. The rise of sedentary lifestyles, rising mental tensions and stress, and unhealthy foods such as fast foods with poor fibre content are some of the risk factors of the above diseases.

Access Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/3841 .

Medication remains the first line treatment for anal fissures and is led by calcium channel blockers and nitro-glycerine ointment. Local anaesthetics are used to manage pain especially during defecation. Topical nitro-glycerine has a side effect of headache which has reduced its use. Stool softeners are another line of medication which are finding greater use. However, chronic use of stool softeners is associated with habituation which is their greatest drawback. Among the stool softeners the lubricants are finding the greatest acceptability than the bulk laxative ones. Docusate salts are the most preferred stool softeners.

The surgical procedures are restricted to patients when medication fails. Development of anal incontinence remains a strong side effect of surgery. Anal incontinence is the loss of ability to control gas and mild fecal soiling. Among the surgeries lateral internal sphincterotomy is preferred to anal dilation. Both internal sphincterotomy and anal dilation involve a general anaesthesia and is painful. Anal stretch has higher chance of developing anal incontinence making lateral internal sphincterotomy the surgery of choice.

The market for the drug treatment of anal fissures is fragmented which has resulted into pressure on profit margins. The stool softeners segment is highly fragmented with plethora of regional players. The loss of patents on other drugs such as calcium channel blockers has resulted in generic penetration and low returns on investments.

Get Attractive Discount @ https://www.marketresearchfuture.com/check-discount/3841 .

Global Anal fissure treatment Market Players:

Key players profiled in the report are SRS Pharmaceuticals Pvt. ltd., Healthy Life Pharma Private Limited, Takeda Pharmaceutical Company Limited, Troikaa Pharmaceuticals Ltd., Novasep, Taj Pharmaceuticals Ltd., PurduePharma L.P., Geri-Care Pharmaceuticals, and others.

Regional analysis

US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. The faster market uptake of new technology in the US is also an important driver of the market for global anal fissure treatment. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is the fastest growing region because of large unmet needs which is led by China and India. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa are expected to be a laggard due to poor economic and political conditions and poor healthcare penetration.

Ask to Expert @ https://www.marketresearchfuture.com/enquiry/3841 .

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.